Dambkowski Carl 4

What Happened
Carl Dambkowski, a director of Oruka Therapeutics, was granted a derivative award for 9,136 shares on 2026-06-02. The reported acquisition price is $0.00 (Acquired = $0), indicating a compensatory grant rather than an open-market purchase. The filing classifies the transaction as a derivative award (code A).

Key Details

• Transaction date: 2026-06-02; Form 4 filed 2026-06-03 (filed promptly).
• Instrument: Derivative award for 9,136 underlying shares; price reported $0.00.
• Vesting: The option/award vests 1/12 of the underlying shares monthly beginning June 2, 2026 (footnote).
• Shares owned after the transaction: Not specified in the provided filing.
• Filing timeliness: Reported the next day (not marked late).

Context
This was a time‑based compensatory grant (derivative security) with monthly vesting over 12 months, which means the insider does not immediately receive fully vested shares. Such awards are typically retention or compensation incentives; any future exercises or sales would be reported separately and could have different implications for ownership and market impact.